18 reports

TVI-TUBERCULOSIS-## - DRUG PROFILE TVI-TUBERCULOSIS-## TVAX BIOMEDICAL INC Mechanism Of Action R& D Progress TVI-TUBERCULOSIS-## IS UNDER DEVELOPMENT FOR THE TREATMENT OF TUBERCULOSIS.

  • Pathology
  • Tuberculosis
  • Vaccine
  • World
  • TB Drug Development, Inc.

TVI-TUBERCULOSIS-## - DRUG PROFILE TVI-TUBERCULOSIS-## TVAX BIOMEDICAL INC Mechanism Of Action R& D Progress TVI-TUBERCULOSIS-## IS UNDER DEVELOPMENT FOR THE TREATMENT OF TUBERCULOSIS.

  • Pathology
  • Tuberculosis
  • Vaccine
  • United States
  • TB Drug Development, Inc.

" We are probably one of a few groups in the world who are actually doing bench-to-human tuberculosis vaccine work, and we are excited to be part of this and thrilled that it started at McMaster. "

  • Tuberculosis
  • Vaccine
  • South Africa
  • World
  • Product Initiative

Similarly, the Universities' portfolio in Phase II and Phase I stages comprises ## and ## molecules, respectively.

  • Tuberculosis
  • Vaccine
  • South Africa
  • World
  • Product Initiative

Tuberculosis, and particularly MDR-TB, represents one of the world' s top health challenges, and is a serious burden and threat for China.

  • Tuberculosis
  • United States
  • World
  • Product Initiative
  • Lycera Corp.

Tuberculosis, and particularly MDR-TB, represents one of the world' s top health challenges, and is a serious burden and threat for China.

  • Tuberculosis
  • United States
  • World
  • Product Initiative
  • Lycera Corp.

The World Health Organization reports that about one-third of the world' s population has been infected by TB bacteria, Mycobacterium tuberculosis.

  • Tuberculosis
  • United States
  • World
  • Product Initiative
  • Spero Therapeutics, LLC

The World Health Organization reports that about one-third of the world' s population has been infected by TB bacteria, Mycobacterium tuberculosis.

  • Tuberculosis
  • United States
  • World
  • Product Initiative
  • Spero Therapeutics, LLC

In September 2006, Cumbre Pharmaceuticals Inc has entered into agreement with Global Alliance for TB Drug Development, a non-profit product development partnership for new tuberculosis (TB) drugs, to develop new agents for tuberculosis therapy.

  • Tuberculosis
  • United States
  • World
  • Product Initiative
  • AmpliPhi Biosciences Corporation

Other Developmental Activities AN-## Product Description Small Molecule ## for Tuberculosis Product Description Small molecule is under development for the treatment of tuberculosis.

  • Pharmaceutical
  • Tuberculosis
  • United States
  • Company Operations
  • Anacor Pharmaceuticals, Inc.

In May 2012 Immune Network Ltd presented one month trial results of oral Mycobacterium vaccae therapeutic vaccine (V##) in ## patients with tuberculosis.

  • Pathology
  • Tuberculosis
  • World
  • Company Operations
  • Immunitor, Inc.

TUBERCULOSIS, M.

  • Breast Cancer
  • Monoclonal Antibody
  • Therapy
  • Tuberculosis
  • Daiichi Sankyo Company

The scientists reported ##, ##-azaindoles as a new inhibitor class that killed Mycobacterium tuberculosis in vitro and demonstrated efficacy in mouse tuberculosis models.

  • Blood Disease
  • Therapy
  • Tuberculosis
  • United States
  • AstraZeneca PLC

One of the hits, indole-##-carboxamide analog (##), had low micromolar potency against Mycobacterium tuberculosis (Mtb), high mouse liver microsomal clearance, and low aqueous solubility.

  • Cancer
  • Targeted Therapy
  • Therapy
  • Tuberculosis
  • Novartis AG

It offers TG## and various candidates for chronic hepatitus B and tuberculosis.

  • Genetically Modified Organism
  • Therapy
  • Transgene
  • Tuberculosis
  • Transgene SA

R& D Progress Research and Development Brief Discovery/ Preclinical Trial Details Small Molecule ## for Tuberculosis Product Description Small molecule for tuberculosis is under development for the treatment of tuberculosis.

  • Infectious Disease
  • Therapy
  • Tuberculosis
  • United States
  • Sanofi S.A.

Tarmogens express antigens from one or more disease-related proteins.

  • Therapy
  • Tuberculosis
  • United States
  • Company Operations
  • GlobeImmune, Inc.

The drug candidate acts by inhibiting mycobacterium tuberculosis dihydrofolate synthetase (Mtb-DHFS).

  • Tuberculosis
  • Turkey
  • United States
  • Company Operations
  • Syntrix Biosystems, Inc.